Congratulations to EpiVax, Inc. which has been awarded a new SBIR Phase II grant from the National Institutes of Health totaling $1.5 million. EpiVax anticipates receiving an additional SBIR award of approximately $775,000 within the next few months, bringing the total to over $2.25 million. The funding will be dedicated to helping move forward treatment for autoimmune diseases.

Senator Sheldon Whitehouse and Congressman Jim Langevin joined the team at EpiVax, Inc. for the announcement of the award at the company’s building in Providence.

Read more….